The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
-
Local Institution - 0032, Anchorage, Alaska, United States, 99508
Local Institution - 0062, Los Angeles, California, United States, 90033
Local Institution - 0063, Boise, Idaho, United States, 83702
Local Institution - 0052, Boise, Idaho, United States, 83706
Local Institution - 0064, Post Falls, Idaho, United States, 83854
Local Institution - 0047, Cleveland, Ohio, United States, 44106
Local Institution - 0033, Cleveland, Ohio, United States, 44109
Local Institution - 0051, Allentown, Pennsylvania, United States, 18103
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2028-10-25